Phase II trial of androgen deprivation therapy (ADT) and pembrolizumab for advanced stage androgenreceptor-positive salivary gland carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

Project: Research project

Description

Phase II trial of androgen deprivation therapy (ADT) and pembrolizumab for advanced stage androgen receptor-positive salivary gland carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
StatusActive
Effective start/end date9/17/189/30/23

Funding

  • BIG TEN CANCER RESEARCH CONSORTIUM

Fingerprint

Androgen Receptors
Salivary Glands
Androgens
Carcinoma
Research
Neoplasms
Therapeutics
pembrolizumab